期刊
CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 20, 期 9, 页码 -出版社
SPRINGER
DOI: 10.1007/s11864-019-0670-1
关键词
Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor; High-grade; PRRT
类别
资金
- Ipsen
- Thermo Fisher Scientific
Opinion statement In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据